Bristol-Myers Squibb Clinical Trial Pipeline: 226 Active Trials, 57 Changes This Month

36 trials changed in the last 30 days: 1 stopped, 10 with notable changes, 25 with minor changes only.

Stopped

BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax · Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Trial terminated

Sponsor's reason: Inability to meet protocol objectives

Also in this update: Trial sites reduced: 16 → 10 locations; Primary completion date changed from estimate of Feb 1, 2027 to Aug 28, 2026

Bristol-Myers SquibbPhase 1 NCT06419634 Registry history of NCT06419634 on ClinicalTrials.gov (opens the registry)

Updated Oct 1, 2026
Notable

Repotrectinib Versus Crizotinib · Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

Primary completion pushed from Mar 13, 2026 to Feb 16, 2027

Bristol-Myers SquibbPhase 3 NCT06140836 Registry history of NCT06140836 on ClinicalTrials.gov (opens the registry)

Updated Sep 22, 2026
Notable

Follow-up Protocol for Participants Treated With Gene-Modified T Cells

Primary and study completion pushed from Nov 30, 2036 to May 29, 2043

Also in this update: Trial sites expanded: 213 → 222 locations

CelgenePhase 2/3 NCT03435796 Registry history of NCT03435796 on ClinicalTrials.gov (opens the registry)

Updated Sep 18, 2026
Notable

CheckMate-67T · Subcutaneous Nivolumab Versus Intravenous Nivolumab · Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread

Primary endpoint(s) modified

Also in this update: Results posted: Sep 22, 2026

Bristol-Myers SquibbPhase 3 NCT04810078 Registry history of NCT04810078 on ClinicalTrials.gov (opens the registry)

Updated Sep 22, 2026
Notable

Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan · Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

Primary endpoint(s) modified

Also in this update: Enrollment increased: 130 → 182 participants; Trial sites reduced: 70 → 67 locations

Bristol-Myers SquibbPhase 2 NCT06855771 Registry history of NCT06855771 on ClinicalTrials.gov (opens the registry)

Updated Sep 18, 2026
Notable

Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

Recruitment opened

Also in this update: Trial sites reduced: 208 → 201 locations

Bristol-Myers SquibbPhase 3 NCT07680790 Registry history of NCT07680790 on ClinicalTrials.gov (opens the registry)

Updated Oct 8, 2026
Notable

Asia Myelodysplastic Syndrome (MDS) Registry

Recruitment opened

Bristol-Myers SquibbNot specified NCT07355478 Registry history of NCT07355478 on ClinicalTrials.gov (opens the registry)

Updated Oct 8, 2026
Notable

Navlimetostat (BMS-986504) Drug Interactions and Food Effect in Healthy Participants

Recruitment opened

Also in this update: Start date changed from estimate of Aug 26, 2026 to Aug 31, 2026

Bristol-Myers SquibbPhase 1 NCT07800897 Registry history of NCT07800897 on ClinicalTrials.gov (opens the registry)

Updated Oct 5, 2026
Notable

ODYSSEY-HCM · Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy

Reclassified as terminated (was completed)

Sponsor's reason: Trial terminated because of lack of efficacy in the short term acute phase

Bristol-Myers SquibbPhase 3 NCT05582395 Registry history of NCT05582395 on ClinicalTrials.gov (opens the registry)

Updated Sep 18, 2026
Notable

Golcadomide · Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function

Recruitment opened

Bristol-Myers SquibbPhase 1 NCT07763418 Registry history of NCT07763418 on ClinicalTrials.gov (opens the registry)

Updated Oct 1, 2026
Notable

Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and · Early Alzheimer's Disease After Multiple Dose Administration

Recruitment opened

Also in this update: Trial sites expanded: 1 → 6 locations

Bristol-Myers SquibbPhase 1 NCT07780383 Registry history of NCT07780383 on ClinicalTrials.gov (opens the registry)

Updated Sep 24, 2026

Show 25 trials with minor changes only

Minor

ONUREG (Oral Azacitidine) · Acute Myeloid Leukemia

Trial completed

Also in this update: Study completion date changed from estimate of Mar 31, 2026 to Feb 28, 2026

Bristol-Myers SquibbNot specified NCT07458542 Registry history of NCT07458542 on ClinicalTrials.gov (opens the registry)

Updated Oct 1, 2026
Minor

Real-world Patient Characteristics, Treatment Patterns, and Healthcare Utilization Among KarXT Users

Trial completed

Bristol-Myers SquibbNot specified NCT07571148 Registry history of NCT07571148 on ClinicalTrials.gov (opens the registry)

Updated Oct 1, 2026
Minor

Treatment Patterns and Effectiveness of Luspatercept

Trial completed

Bristol-Myers SquibbNot specified NCT06971185 Registry history of NCT06971185 on ClinicalTrials.gov (opens the registry)

Updated Sep 30, 2026
Minor

BMS-986489 · Relapsed/Refractory Small Cell Lung Cancer

Trial completed

Also in this update: Primary completion date changed from estimate of May 26, 2027 to Sep 9, 2026

Bristol-Myers SquibbPhase 1 NCT06799286 Registry history of NCT06799286 on ClinicalTrials.gov (opens the registry)

Updated Sep 24, 2026
Minor

Drug Levels and Safety of BMS-986435 · Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment

Trial completed

Also in this update: Final enrollment: 69 participants (planned 24)

Bristol-Myers SquibbPhase 1 NCT07248839 Registry history of NCT07248839 on ClinicalTrials.gov (opens the registry)

Updated Sep 21, 2026
Minor

Navlimetostat Tablet Formulations

Primary completion pushed from Aug 31, 2026 to Nov 2, 2026

Bristol-Myers SquibbPhase 1 NCT07544628 Registry history of NCT07544628 on ClinicalTrials.gov (opens the registry)

Updated Oct 7, 2026
Minor

SUCCESSOR-2 · Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) · Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

Primary completion pushed from Jul 18, 2026 to Sep 28, 2026

Also in this update: Trial sites reduced: 207 → 204 locations

Bristol-Myers SquibbPhase 3 NCT05552976 Registry history of NCT05552976 on ClinicalTrials.gov (opens the registry)

Updated Sep 24, 2026
Minor

rechARge · BMS-986365 Versus the Investigator's Choice of Therapy · Metastatic Castration-resistant Prostate Cancer

Trial sites expanded: 212 → 227 locations

CelgenePhase 3 NCT06764485 Registry history of NCT06764485 on ClinicalTrials.gov (opens the registry)

Updated Sep 30, 2026
Minor

Pumitamig Versus Pembrolizumab · Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Trial sites expanded: 279 → 284 locations

Bristol-Myers SquibbPhase 3 NCT07361510 Registry history of NCT07361510 on ClinicalTrials.gov (opens the registry)

Updated Sep 30, 2026
Minor

MSS · BMS-986368 · Multiple Sclerosis Spasticity

Trial sites expanded: 55 → 58 locations

CelgenePhase 2 NCT06782490 Registry history of NCT06782490 on ClinicalTrials.gov (opens the registry)

Updated Oct 1, 2026
Minor

KarXT + KarX-EC · Irritability in Children and Adolescents With Autism Spectrum Disorder

Trial sites expanded: 63 → 67 locations

Bristol-Myers SquibbPhase 3 NCT07285798 Registry history of NCT07285798 on ClinicalTrials.gov (opens the registry)

Updated Sep 28, 2026
Minor

Deucravacitinib Versus Ustekinumab · Psoriasis (PRAGMATYK)

Trial sites expanded: 402 → 408 locations

Bristol-Myers SquibbPhase 3 NCT07116967 Registry history of NCT07116967 on ClinicalTrials.gov (opens the registry)

Updated Sep 22, 2026
Minor

KarXT + KarX-EC · Agitation Associated With Alzheimer's Disease (ADAGIO-1)

Trial sites expanded: 159 → 162 locations

Bristol-Myers SquibbPhase 3 NCT07011732 Registry history of NCT07011732 on ClinicalTrials.gov (opens the registry)

Updated Sep 16, 2026
Minor

KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

Trial sites reduced: 256 → 252 locations

Bristol-Myers SquibbPhase 3 NCT06937229 Registry history of NCT06937229 on ClinicalTrials.gov (opens the registry)

Updated Sep 16, 2026
Minor

KarXT · Manic Episodes in Bipolar-I Disorder (BALSAM-3)

Trial sites expanded: 174 → 182 locations

Bristol-Myers SquibbPhase 3 NCT06929273 Registry history of NCT06929273 on ClinicalTrials.gov (opens the registry)

Updated Sep 14, 2026
Minor

RELATIVITY1093 · Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Trial sites expanded: 322 → 326 locations

Bristol-Myers SquibbPhase 3 NCT06561386 Registry history of NCT06561386 on ClinicalTrials.gov (opens the registry)

Updated Sep 14, 2026
Minor

Pumitamig Alone or in Combination With Other Agents · Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

Trial sites expanded: 92 → 96 locations

Bristol-Myers SquibbPhase 1/2 NCT07293351 Registry history of NCT07293351 on ClinicalTrials.gov (opens the registry)

Updated Sep 14, 2026
Minor

Drug Levels of BMS-986369 (Golcadomide) · Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

Primary completion date changed from estimate of Jan 30, 2027 to Aug 11, 2026

Bristol-Myers SquibbPhase 1/2 NCT06035497 Registry history of NCT06035497 on ClinicalTrials.gov (opens the registry)

Updated Oct 7, 2026
Minor

Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment · Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Interventions modified

Also in this update: Start date changed from estimate of Aug 31, 2026 to Sep 10, 2026; and 1 more change in the last 30 days

Bristol-Myers SquibbPhase 2 NCT07680764 Registry history of NCT07680764 on ClinicalTrials.gov (opens the registry)

Updated Oct 2, 2026
Minor

MEMENTO · Mavacamten Impact on Myocardial Structure · Symptomatic Obstructive Hypertrophic Cardiomyopathy

Completion moved earlier from Jul 10, 2027 to Jun 10, 2027

Bristol-Myers SquibbPhase 4 NCT06112743 Registry history of NCT06112743 on ClinicalTrials.gov (opens the registry)

Updated Sep 16, 2026
Minor

QUINTESSENTIAL · Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy · Relapsed or Refractory Multiple Myeloma

Primary completion date changed from estimate of Jun 30, 2027 to Jul 31, 2026

Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyPhase 2 NCT06297226 Registry history of NCT06297226 on ClinicalTrials.gov (opens the registry)

Updated Sep 14, 2026
Minor

Whether · Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

Completion moved earlier from Feb 26, 2027 to Dec 21, 2026

Bristol-Myers SquibbPhase 2 NCT06101134 Registry history of NCT06101134 on ClinicalTrials.gov (opens the registry)

Updated Sep 14, 2026
Minor

Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain

Completion pushed from May 31, 2026 to Nov 27, 2026

Bristol-Myers SquibbNot specified NCT07465029 Registry history of NCT07465029 on ClinicalTrials.gov (opens the registry)

Updated Oct 1, 2026
Minor

COLLIGO-HCM · Real-World Effectiveness of Mavacamten · Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Completion pushed from Jun 30, 2026 to Dec 31, 2026

Bristol-Myers SquibbNot specified NCT06372457 Registry history of NCT06372457 on ClinicalTrials.gov (opens the registry)

Updated Sep 30, 2026
Minor

Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US

Completion pushed from Dec 31, 2025 to Dec 31, 2027

Bristol-Myers SquibbNot specified NCT07107373 Registry history of NCT07107373 on ClinicalTrials.gov (opens the registry)

Updated Sep 30, 2026

Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.

First posted	Trial	Phase	Status
2026-10-01	NCT07852884 First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in Spain		Active, Not Recruiting
2026-10-01	NCT07852962 Study to Assess Drug Levels, Immune Response, Safety and Tolerability of BMS-986446 in…	Phase 1	Not Yet Recruiting
2026-09-30	NCT07848295 A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear…	Phase 1	Not Yet Recruiting
2026-09-29	NCT07846059 Evaluation of Mavacamten-Based Practice in Chinese Adults With Obstructive Hypertrophic…		Not Yet Recruiting
2026-09-23	NCT07837115 A Study to Assess the Relative Bioavailability of Irafamdastat (BMS-986368) and to Assess…	Phase 1	Not Yet Recruiting

NCT ID	Title	Condition	Status	Updated
Phase 4
NCT06875960	A Study to Continue the Administration of Deucravacitinib in Participants With Systemic…	Systemic Lupus Erythematosus (SLE)	Recruiting	2026-09-09
NCT07221877	A Study to Evaluate the Effect of KarXT on Urological Safety	Schizophrenia	Recruiting	2026-06-03
NCT06112743	A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With…	Cardiomyopathy, Hypertrophic	Active, Not Recruiting	2026-09-16
NCT05891249	A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of…	Anemia	Active, Not Recruiting	2026-08-31
NCT07459543	A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose…	Unresectable Melanoma	Not Yet Recruiting	2026-08-12
NCT07004972	A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India…	Symptomatic Obstructive Hypertrophic Cardiomyopathy	Active, Not Recruiting	2026-04-28
NCT06396039	A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With…	Relapsing Multiple Sclerosis	Active, Not Recruiting	2025-04-16
Phase 3
NCT06976203	A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment…	Alzheimer's Disease	Recruiting	2026-10-08
NCT07011745	A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment…	Alzheimer's Disease	Recruiting	2026-10-08
NCT07680790	Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus…	Non-Small Cell Lung Cancer	Recruiting	2026-10-08
NCT06869551	A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165)…	Juvenile Psoriatic Arthritis	Recruiting	2026-10-06
NCT06976216	A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment…	Alzheimer's Disease	Recruiting	2026-10-06
NCT07288567	A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia…	Schizophrenia	Recruiting	2026-10-06
NCT05519085	A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus…	Relapsed or Refractory Multiple Myeloma	Recruiting	2026-09-30
NCT07361497	A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation…	Non-small Cell Lung Cancer (NSCLC)	Recruiting	2026-09-30
NCT07361510	A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With…	Non-Small Cell Lung Cancer (NSCLC)	Recruiting	2026-09-30
NCT06937229	A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in…	Alzheimer Disease	Recruiting	2026-09-28
NCT06951711	A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes…	Bipolar Disorder Type I With Mania or Mania With Mixed Features	Recruiting	2026-09-24
NCT06561386	A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs…	Non-small Cell Lung Cancer	Recruiting	2026-09-23
NCT06951698	A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes…	Bipolar-I Disorder With Mania or Mania With Mixed Features	Recruiting	2026-09-22
NCT07116967	Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With…	Plaque Psoriasis	Recruiting	2026-09-22
NCT07011732	A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment…	Alzheimer Disease	Recruiting	2026-09-16
NCT06615479	A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in…	Relapsed or Refractory Multiple Myeloma (RRMM)	Recruiting	2026-09-15
NCT06929273	A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in…	Bipolar Disorder Type I With Mania	Recruiting	2026-09-14
NCT06646276	A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed…	Extensive-Stage Small Cell Lung Cancer	Recruiting	2026-09-11

Bristol-Myers Squibb clinical trial pipeline

What changed in the last 30 days

New trial filings, last 30 days

Active trials by phase

Active trials top 25 of 226

Disease areas by active trials, top 10 of 46